RAD BioMed Accelerator

RAD BioMed is one of the more durable institutional structures in the Israeli medical device ecosystem, and its model is more specific than the accelerator label suggests. Operating from Tel Aviv as a family office vehicle, RAD BioMed has spent more than a decade backing early-stage biomedical hardware teams with a combination of pre-seed capital, dedicated physical infrastructure, scientific advisory access and operational guidance through the period before traditional seed investors are willing to engage. The firm has been notably consistent through cycles, and its portfolio includes a meaningful share of the medical device companies that have gone on to attract tier-one Israeli and international capital, including the recent Edwards Lifesciences acquisition of Vectorious Medical Technologies in a USD 497 million deal in late 2025.

The stated thesis is straightforward: invest at the earliest possible stage in highly technical diagnostic and therapeutic hardware teams, with a preference for proprietary technology rather than incremental device improvement. RAD BioMed’s edge is structural rather than thesis-driven; the firm provides physical lab and prototyping infrastructure that medical device founders cannot easily replicate, alongside scientific advisors with deep clinical credibility. The team has been explicit that it backs founders before product, before clinical validation and often before a complete management team, accepting the risk in exchange for meaningful equity participation. The firm does not pursue digital health, AI-only platforms or pure pharmaceuticals; it is a hardware accelerator with a clinical bias.

The portfolio reflects that focus and is unusually deep for an early-stage vehicle. Vectorious Medical Technologies developed the world’s first miniature implant for left atrial monitoring and was acquired by Edwards Lifesciences for USD 497 million in September 2025, providing a marquee exit for the firm. Laminate Medical Technologies builds implanted devices for renal vascular procedures in dialysis patients, Perflow Medical develops devices for neurovascular disorders, and Z-square has built a microendoscope platform for minimally invasive imaging and treatment. The broader portfolio includes Advanced Ophthalmic Pharma, REE, BELKIN Laser, Moebius Medical, VGS, SoftWheel, FEMSelect EnPlace, Everads Therapy, SynVaccine, ImmunArray and InnerCore Medical, spanning ophthalmology, cardiology, neurovascular and women’s health hardware. For founders, the Vectorious exit is the most relevant signal: RAD BioMed-formed companies have a credible track record of reaching strategic acquisitions at meaningful valuations.

On stage and check size, RAD BioMed operates at pre-seed and seed with initial commitments typically below USD 250,000. The capital is paired with infrastructure access, scientific advisory and operational support, and the implicit deal is that a meaningful equity stake at formation funds the bundled package rather than the cash alone. Founders should expect the engagement to extend over multiple years before a conventional Series A becomes appropriate, and the firm has demonstrated willingness to support portfolio companies through the gap with bridge participation when needed. The model is not designed for founders who want a passive check; it is designed for technical teams that need lab space, prototyping support and clinical advisor introductions in addition to capital.

Decision-making sits with the RAD BioMed team in Tel Aviv. The firm operates as a family office structure rather than a traditional fund with a partner committee, which gives the team flexibility on sizing and timing that a typical accelerator does not have. Diligence focuses heavily on technical feasibility and clinical relevance, with less emphasis on commercial narrative at formation. The firm is comfortable backing teams before they have a complete management roster.

The most reliable approach is through Israeli academic and clinical channels. RAD BioMed has long relationships with Israeli research institutes, hospitals and clinical advisors, and warm referrals from those networks materially improve the conversion rate. Direct outreach through the firm’s website is read, but founders are better served arriving with a clinical advisor reference and a clear technical differentiation story. The firm’s intake cycles are not as structured as larger Israeli incubators, which means timing matters less and substance matters more.

What founders should know is that RAD BioMed is a hardware-first investor with a long horizon and a willingness to be patient through the development cycle, and that the structural support package is genuinely differentiated for medical device teams that lack their own infrastructure. Equity expectations are meaningful at formation, the engagement is operationally involved, and the firm will not be a fit for founders who want capital without infrastructure. For Israeli medical device builders with proprietary technology and clinical ambition, RAD BioMed remains one of the most credible formation-stage partners in the region.